dc.contributor.author
Ortiz-Maldonado Gibson, Valentín
dc.contributor.author
Frigola, Gerard
dc.contributor.author
Español Rego, Marta
dc.contributor.author
Balagué, Olga
dc.contributor.author
Martínez Cibrian, Nuria
dc.contributor.author
Magnano, Laura
dc.contributor.author
Giné Soca, Eva
dc.contributor.author
Pascal i Capdevila, Mariona
dc.contributor.author
Correa, Juan G.
dc.contributor.author
Martínez Roca, Alexandra
dc.contributor.author
Cid Vidal, Joan
dc.contributor.author
Lozano Molero, Miguel
dc.contributor.author
Villamor i Casas, Neus
dc.contributor.author
Benítez-Ribas, Daniel
dc.contributor.author
Esteve Comas, Jordi
dc.contributor.author
López Guillermo, Armando
dc.contributor.author
Campo Güerri, Elias
dc.contributor.author
Urbano Ispizua, Álvaro
dc.contributor.author
Juan, Manel
dc.contributor.author
Delgado, Julio (Delgado González)
dc.date.issued
2023-05-08T09:43:51Z
dc.date.issued
2023-05-08T09:43:51Z
dc.date.issued
2022-01-31
dc.date.issued
2023-05-02T07:59:08Z
dc.identifier
https://hdl.handle.net/2445/197660
dc.description.abstract
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic
leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated
with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient
with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5%
grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced
absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median
follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In
conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high risk CLL or RT
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fonc.2022.828471
dc.relation
Frontiers In Oncology, 2022, vol.12, num. 828471
dc.relation
https://doi.org/10.3389/fonc.2022.828471
dc.rights
cc by (c) Ortiz Maldonado, Valentín et al., 2022
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Leucèmia limfocítica crònica
dc.subject
Teràpia cel·lular
dc.subject
Chronic lymphocytic leukemia
dc.subject
Cellular therapy
dc.title
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
